Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-01 in Recurrent/Metastatic Colorectal Cancer
NCT07314294Phase 2Recruiting
- Sponsor
- EpimAb Biotherapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emb-01 in metastatic colorectal cancer (mCRC), sponsored by EpimAb Biotherapeutics. Started Dec 2025; status: recruiting.
02
Drugs
emb-01
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07314294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314294.